Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with HLS Therapeutics for exclusive commercialization rights of NEXLETOL and NEXLIZET in Canada. The agreement includes an upfront payment, milestone payments up to $5 million, and tiered royalties on product sales. Esperion will supply the finished product at a profitable transfer price.
The partnership aims to address a significant market, as approximately 2.6 million Canadian adults live with diagnosed heart disease, which is the second leading cause of death in Canada. HLS will handle commercialization, reimbursement, and marketing responsibilities in Canada, while Esperion maintains product supply duties.
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming Citizens Life Sciences Conference scheduled for May 8, 2025, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days.
Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.
Esperion (NASDAQ: ESPR) announced new research for treating Primary Sclerosing Cholangitis (PSC), a rare liver disease, at their R&D Day 2025. The company unveiled lead candidates, including ESP-1336, which are novel allosteric inhibitors of ATP citrate lyase (ACLY) targeting hepatic inflammation and fibrosis.
The preclinical data shows promising results in reducing liver injury, inflammation, and fibrosis across multiple PSC-relevant models. The company's research utilized multi-omics and phenome-wide association studies to identify ACLY mechanisms linked to bile duct injury and PSC progression.
The market opportunity is estimated at over $1 billion annually, with approximately 76,000 diagnosed PSC patients across the U.S. and Europe as of 2024. The program may be eligible for Orphan Drug and Fast Track designations from the FDA.
Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.
The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.
Esperion (NASDAQ: ESPR) has announced an upcoming R&D Day scheduled for April 24, 2025, at 9:00 a.m. ET in New York City. The event will showcase the company's research developments in ATP citrate lyase (ACLY) biology and its therapeutic applications for various life-threatening conditions.
The presentation will focus on how ACLY inhibitors could treat rare and chronic liver and kidney diseases. Esperion plans to reveal a new indication and introduce their lead candidate's development pathway. The event will feature key opinion leaders including Dr. Christos S. Mantzoros from Harvard Medical School and Dr. David E. Cohen from Brigham and Women's Hospital.
A live webcast will be available with pre-registration required on Esperion's website Investor section, with replay available for approximately 90 days after the event. In-person attendance requires advanced registration.
Esperion (NASDAQ: ESPR) has announced significant changes to its Board of Directors. Robert E. Hoffman has been appointed as an independent director, effective immediately, and will serve as Chairperson of the Audit Committee starting May 29, 2025. Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board effective June 1, 2025.
Hoffman brings extensive experience in the biopharmaceutical sector, having served as President, CEO, interim CFO, and Chairperson at Kintara Therapeutics (2021-2024). His previous roles include senior positions at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals. He currently serves on the boards of TuHURA Biosciences and Fibrobiologics, and has been a board member for several public and private life sciences companies.
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference scheduled for April 7, 2025, at 8:45 a.m. ET. The event will be accessible via webcast through Esperion's website, with replay available for approximately 90 days.
Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function for rational drug design. Esperion continues to expand globally through commercial execution, international partnerships, and pre-clinical pipeline development.
Esperion (NASDAQ: ESPR) has received FDA alignment to proceed with Phase 3 clinical trials of bempedoic acid, both alone and combined with ezetimibe, for pediatric patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH).
The company plans to initiate these Phase 3 studies in 2025, following successful completion of Phase 2 clinical study enrollment. The FDA has previously granted orphan drug designation for bempedoic acid in HoFH indication.
This development will allow Esperion to extend its patent protection for an additional six months through June 2031, as part of their lifecycle management plan for bempedoic acid products.
Esperion (NASDAQ: ESPR) reported strong financial results for Q4 and FY 2024, with total revenue growing 186% year-over-year to $332.3 million. U.S. net product revenue increased 48% to $115.7 million for FY24, while Q4 total revenue rose 114% to $69.1 million.
The company's Q4 retail prescription equivalents grew 45% Y/Y and 12% Q/Q, with expanded prescriber base now totaling over 25,000 healthcare practitioners. Esperion announced development of triple combination products with bempedoic acid in the U.S., potentially offering LDL-C lowering exceeding 60%.
Key highlights include:
- Products now approved in 39 countries globally
- Expanded payer access covering 173 million lives
- Otsuka submitted New Drug Application in Japan
- Net loss improved to $51.7 million in FY24 from $209.2 million in FY23
- Cash position strengthened to $144.8 million as of December 31, 2024